Jyong Biotech
MENS
17 hedge funds and large institutions have $904K invested in Jyong Biotech in 2026 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 2 reducing their positions, and 4 closing their positions.
450% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 2
0.06% less ownership
Funds ownership: 0.64% → 0.58% (-0.06%)
11% less funds holding
Funds holding: 19 → 17 (-2)
37% less capital inflows, than outflows
Capital inflows: $153K | Capital outflows: $243K
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$52K |
| 2 |
Citigroup
New York
|
+$40.9K |
| 3 |
StoneX Group
New York
|
+$33.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.9K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$5.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
-$104K |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
-$60.2K |
| 3 |
Renaissance Technologies
New York
|
-$47.4K |
| 4 |
State of Wyoming
Cheyenne,
Wyoming
|
-$23.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.7K |
MENS Hedge Fund Activity: Q3 2026 in Review
17 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Jyong Biotech (MENS) for Q3 2026, worth a combined $904K — down 11% from $1.01M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MENS and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 11 added.
The largest buyer was BlackRock, adding an estimated $52K. The largest seller was HRT Financial, exiting entirely with an estimated $104K sold.
- 17 institutional investors held Jyong Biotech (MENS) as of Q3 2026, down from 19 in Q2 2026.
- Funds reported $904K of Jyong Biotech stock for Q3 2026, down 11% quarter-over-quarter.
- 2 funds opened new Jyong Biotech positions in Q3 2026 and 4 closed out, a net change of -2 holders.
- The largest Jyong Biotech buyer in Q3 2026 was BlackRock, an estimated $52K added.
- The largest Jyong Biotech seller in Q3 2026 was HRT Financial, an estimated $104K sold.
Based on aggregated 13F filings for Q3 2026.